ABSTRACT
␤-amyloid hypothesis (1) and aberrant tau metabolism (2) to a combination of genetic (apolipoprotein E polymorphism) (3) and nongenetic risk factors, such as age, and a reduction of neuronal activity (4) . Regarding the genetic contribution, only a minority of cases concerns autosomal dominant forms of AD with mutations in the ␤-amyloid precursor protein (APP) or the presenilin genes (5) . The presence of one or two ApoE4 alleles can contribute to neurodegeneration in ϳ30% of all AD cases (3) .
We earlier reported on a novel type of transcript mutation in neurons of elderly people and in those of sporadic AD and Down syndrome (DS) patients (6, 7) . In these patients, dinucleotide deletions (⌬GA, ⌬GU, ⌬CU) were found in two transcripts (i.e., ␤APP and ubiquitin B, UBB) implicated in these neurodegenerative diseases (7) . Hot spots for these dinucleotide deletions appear to be simple repeats, such as GAGAG motifs (8) . The process of unfaithful transcription of genomic information into aberrant mRNA and the subsequent production of frameshifted proteins has been termed "molecular misreading" (9) . These mutant proteins, carboxyl-terminally translated in the ϩ1 reading frame of the mRNA, have been called ϩ1 proteins. In Alzheimer disease and Down syndrome, APP ϩ1 and UBB ϩ1 accumulate in affected regions of the brain and coexist in the neuritic plaques and tangles (7) . During the development of neuropathology and/or aging, neurons either start producing aberrant transcripts or lose the ability to degrade these transcripts and ϩ1 proteins. In other words, during aging and particularly in neurodegenerative disease, transcript and protein quality control mechanisms, such as proteasomal protein degradation, may work less efficiently (9) . Several groups have already shown that UBB ϩ1 protein blocks the proteasome (10, 11) , which can result in neuronal apoptosis (12) .
The accumulation of UBB ϩ1 protein in the hallmarks of AD and DS raises the question whether the manifestation of molecular misreading is restricted to these forms of dementia or whether it occurs in other nonAlzheimer type neurodegenerative diseases (i.e., the tauo-and synucleinopathies) as well. In a great number of neurodegenerative disease, ubiquitin or ubiquitinated proteins accumulate, which are thought to be involved in the development of these diseases (18) . In the present study we examined the major forms of tauopathiesOPick disease (PiD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and argyrophilic grain disease (AGD) (13, 14) Oand the most frequently occurring forms of synucleinopathies (15, 16) OLewy body disease (LBD, clinically Parkinson's disease) and multiple system atrophy (MSA)Ofor the presence of mutant ubiquitin. We detected a clear difference in UBB ϩ1 -containing inclusions between tauopathies and synucleinopathies. Experiments performed with lentiviral vectors in the rat hippocampus indicate that proteasomal dysfunction could be the reason for the differential accumulation in neurodegenerative disease.
MATERIALS AND METHODS

Ligase chain reaction
Detection of UBB mRNA containing a GU dinucleotide deletion was performed using a ligase chain reaction (LCR) (17) . Two micrograms of total RNA was reverse-transcribed with hexanucleotides and Expand reverse transcriptase (Roche Diagnostics Nederland BV, Almere, The Netherlands). The UBB cDNA was amplified by PCR using primers 5ЈACCGGCAAGACCATCACCCT and 5Ј-GGGTCTTCAC-GAAGATCTGCA and Expand High Fidelity polymerase (Roche). The PCR product was purified on silica powder in guanidine thiocyanate and used in a ligase chain reaction of 20 L containing 20 mM Tris-Cl (pH7.5), 20 mM KCl, 10 mM MgCl 2 , 0.1% NP-40, 0.01 mM ATP, 1 mM DTT, 5 g salmon sperm DNA, 8 u Pfu DNA ligase (Stratagene Europe, Amsterdam, The Netherlands), and 5 pmol of each oligonucleotide: 5Ј-TTCCTGGTCCTGCGTCTGAGAGG, 5Ј-phosphate-CTCT-CAGACGCAGGACCAGG, 5Ј-phosphate-GTATGCAGATCT-TCGTGAAGACC, 6-FAM-5ЈTTGTCTTCACGAAGATCTGCA-TACC. Reaction conditions were: 4 min 92°C, 4 min 65°C, 35 cycles of 20 s 92°C, 20 s 65°C. Samples were run on an 8% polyacrylamide gel and scanned with a STORM 860 imager (Molecular Dynamics, Sunnyvale, CA, USA). Sensitivity of the ⌬GU LCR was 10 amol dsDNA; specificity was 1 ⌬GU cDNA in 80,000 wild-type UBB cDNA.
Autopsy material
Postmortem material of the major types of tauopathies and synucleinopathies was obtained from different sources (Pathological Laboratory Oost-Nederland, Enschede; Netherlands Brain Bank, Amsterdam and Utrecht Medical Center). We were able to identify almost pure forms of each type of neurological disorder by neurohistological prescreenings, excluding cases showing a combination of different neuropathological entities, such as Lewy body disease and AD. All these neurological disorders were studied in 6 m paraffin sections using reported immunocytochemical methodology (7).
Antibodies
Specificity (including Western blot analysis, ref 12) of four different UBB
ϩ1 antisera [rabbits were immunized with different specific peptides of the UBB ϩ1 protein: Y-Q (11AA, #160294), UBB1ϩ1, R-Q (11AA, UBB 2ϩ1, #010994, and #020698 Ubi2A), and Y-Q (20AA, # 050897, Ubi3] has been reported before (7, 12) and was confirmed in the present study (Fig. 2) . Absorption with the homologous antigen resulted in an absence of staining. Other antibodies were used as the positive immunohistochemical controls: MC 1 and AT 8, both markers for aberrant or hyperphosphorylated tau (19) ; human leukocyte antigen (HLA) DP-DR-DQ (CR3/43, DAKO) for activated microglia; 22C11, a gift from Dr. T. Hartmann, Heidelberg, Germany, for ␤APP; MoAb 3-39 (7) and a rabbit antibody (Z 0458, DAKO, Glostrup, Denmark) for ubiquitin; NCL-A SYN (clone KM51, Novacastra) for ␣-synuclein.
Lentiviral injections
cDNAs for GFP, UBB ϩ1 , and UBB ϩ1 containing a Lys to Arg mutation at positions 29 and 48 were cloned in the lentiviral transfer plasmid pRRLsin-PPThCMV-GFP-pre (20, 21) . VSV-G pseudotyped lentivirus was produced by cotransfection of the transfer plasmid and helper plasmids (pCMVdeltaR8.74 and pMD.G.2) in 293T cells. Medium was harvested 24 and 48 h after transfection and concentrated by ultracentrifugation. Virus pellets were resuspended in PBS containing 0.5% bovine serum albumin. Stocks were titered with a HIV-1 p24 coat protein ELISA (NEN Research, Boston, MA, USA). Lentiviral vectors were used to infect SH-SY5Y neuroblastoma cells at a multiplicity of infection (moi) of 10. After 48 h epoxomicin was added to the culture medium (0.5 M, Affinity Research, Exeter, UK) for 16 h to inhibit the proteasome. Cells were scraped in Laemmli buffer and analyzed on Western blot (Ubi3 antibody). Detection was performed with enhanced chemiluminescence (ECL, Perkin-Elmer Life Science, Norwalk, CT, USA).
Before injection into rat brain, stocks for LV-UBB ϩ1 and GFP (green fluorescent protein) were mixed and diluted with PBS containing 0.5% BSA, resulting in 4.10 5 particles LV-UBB ϩ 1 and 4.10 4 particles LV-GFP per microliter. Male adult Wistar rats (200 -250 g, Harlan NL, nϭ3) were anesthestized with 1 mL/kg Hypnorm (0.315 mg/mL fentanyl citrate, 10 mg/mL fluanisone). The skull was exposed and coordinates for injection (-3.3 mm anterior-posterior, 1.7 mm lateral, and -3.5 dorsoventral from the dura) were read against bregma (22) . Stereotactic injection of 1 L was performed with a 30G stainless steel needle connected to a motor-driven Hamilton syringe for 5 min at 0.2 L/min. After the needle was slowly (over 5 min) withdrawn, the skin was sutured. Seven days after injection the animals were perfused intracardially with PBS, followed by PBS containing 4% paraformaldehyde. Brains were cut on a vibratome in 50 m-thick sections and stained with anti-UBB ϩ1 (Ubi3, 1:500) or anti-GFP (Chemicon AB3080 1:50) serum, followed by a peroxidase/anti-peroxidase sandwich and DAB-Ni color reaction. GFP was imaged directly with confocal laser scanning microscopy (Zeiss LSM 410), whereas UBB ϩ1 protein was visualized with the Ubi3 antibody and donkey anti-rabbit Cy3. DNA was counterstained with TO-PRO-3 (Molecular Probes, Leiden, The Netherlands). All animal experiments were performed under the guidance of the local animal experimentation committee.
RESULTS
UBB mRNA with a dinucleotide deletion is not disease-specific
To analyze dinucleotide deletions (⌬GU) in ubiquitin-B transcripts in an array of neurological disorders, we analyzed the mRNA from a large number of samples. The mRNA was isolated from the areas affected in the disease studied (e.g., hippocampus in Pick disease, amygdala in AGD, Table 1 and Table 2 ). A new strategy was followed, enabling a sensitive and specific assessment of molecular misreading of the UBB gene at the mRNA level. Dinucleotide deletions (⌬GU) in UBB mRNA are detected by a ligase chain reaction (LCR) (17, 23) . In this assay four primers flank the GT dinucleotide in UBB cDNA. If these primers hybridize on a cDNA lacking this dinucleotide, adjacent oligonucleotides can be ligated by a thermostable ligase. The ligated oligonucleotides are a substrate in the subsequent rounds of amplification. If the oligonucleotides hybridize on wild-type UBB cDNA (which is present in excess), the high reaction temperature and specificity of the ligase do not allow ligation. We can detect UBB mRNA containing a dinucleotide deletion in every tested brain sample of all types of neurological disorders, but not in samples of genomic DNA or in various neuronal cell lines ( Fig. 1 and Table 1 ). Unexpectedly, even brain samples (hippocampus and cortex) of young nondemented controls (i.e., 38 -49 years old) contain UBB⌬GU mRNA.
Neuropathological hallmark identification and antibody specificity studies
Characteristic neuropathological hallmarks of each disease (e.g., Pick bodies and tangles, see also legends of Fig. 2 and Fig. 3 ) were first positively identified using antibodies against aberrant, hyperphosphorylated tau (13, 19) , ubiquitin, or ␣-synuclein (15) (Fig. 3 and Fig.  4 , left and right column, Table 1 ). In consecutive sections of the hippocampus of four Pick patients (boldface in Table 2 ), four UBB ϩ1 antisera directed against three different epitopes stained the same population of pyramidal cells in the CA1 area ( Fig. 2a-d) . Antibody specificity controls for UBB ϩ1 staining (e.g., preabsorption with the antigen) were negative (Fig. 2e) . ϩ1 protein is observed in a subpopulation of the ubiquitin-positive inclusions, such as Pick bodies in PiD (granular cells of the dentate gyrus of the hippocampus and pyramidal cells in the CA1 area), neurofibrillary and glial tangles in gray matter of the prefrontal cortex in PSP, and coiled bodies in white matter of PSP (Fig. 3i) . These data show that besides neurons, glial cells can express proteins derived from mRNAs with dinucleotide deletions. In all AGD cases (13, 25) , grains in the amygdala (Fig. 3m) and hippocampus (not shown) are very intensely labeled by the UBB ϩ1 antibodies. In cases of FTD, a disease that can be linked to a mutation in tau (26 -27) (see Tables 1 and 2 for details and type of mutation), three of eight examples show UBB ϩ1 protein staining (Fig. 3e) . The immunopositive structures, such as cytoplasmic inclusions in the dentate gyrus (globoid tangles) and pyramidal cells of the CA1 of the hippocampus, are also positive for abnormal, hyperphosphorylated tau and for ubiquitin. The heterogeneity in the clinical phenotype of frontotemporal dementia, perhaps reflected here in the heterogeneous UBB ϩ1 protein staining, has recently been discussed (27) (28) . The observation that in most cases ubiquitin staining is more intense than UBB ϩ1 staining could be due to sensitivity; for instance, ubiquitinated UBB ϩ1 with several ubiquitin molecules attached, ref 10) has only one epitope for anti-UBB ϩ1 , but most likely several epitopes for ubiquitin antibodies. On the other hand, this difference in staining pattern could reflect the accumulation of UBB ϩ1 after the accumulation of other ubiquitinated proteins.
Tauopathies
Synucleinopathies
We have examined two synucleinopathies: Lewy body disease (clinically Parkinson disease) and MSA. We failed to detect UBB ϩ1 -positive inclusions in LBD, Lewy neurites, or cortical or classical Lewy bodies (Fig. 4a-c) in an even larger group of patients than previously reported (7). MSA reveals no detectable UBB ϩ1 protein (Fig. 4e) , whereas ␣-synuclein (Fig. 4d ) and ubiquitin (Fig. 4f ) stainings were intense.
UBB
؉1 does not accumulate due to neuronal damage or overactivation
To investigate the mechanism for the differential accumulation of UBB ϩ1 in neurodegenerative disease, we checked the expression of UBB ϩ1 protein in two other neurological diseases (multiple sclerosis and epilepsy) as a control for neuronal damage or overactivation, respectively. UBB ϩ1 protein was not detected in areas Table 1 (n ϭ 21) were reported previously (7) as well.
d Pick's disease: numbers in boldface were used for specificity studies (Fig. 2) . In Pick's disease all cases were positive for hyperphosphorylated Tau (MC1) or ubiquitin, whereas the tangle load was absent or minimal. In frontotemporal dementia, no Pick bodies were found whereas the tangle load varied between minimal and severe. In patient #99005 globoid tangles were reported (Fig.  3d-f ) . Patient #96498 was suggested to have FTD with motor neuron disease. Table 2 by an asterisk (*).
surrounding the various types of plaques in multiple sclerosis (29) , whereas ␤APP could be readily detected in damaged axons (29) and HLA-expressing microglia can be seen in an active lesion (Fig. 5) . Furthermore, in the hippocampal area in temporal lobe epilepsy, we did not detect UBB ϩ1 (data not shown). These data suggest that UBB ϩ1 accumulation is not a secondary response to neurodegeneration.
UBB
؉1 is degraded by the ubiquitin-proteasome system in the hippocampus
Our findings indicate that in syncleinopathies and control subjects (7), either UBB ϩ1 mRNA is not translated or, which is more likely, the degradation of UBB ϩ1 protein occurs very efficiently as we have shown in cell lines (11) . The degradation in vitro of UBB ϩ1 is Figure 2 . Consecutive sections (a-c) of the hippocampus of a Pick's disease patient (#93082) incubated with three different UBB ϩ1 antisera. a) Ubi 1ϩ1 #160294;1;300, b) Ubi 2ϩ1 #010994;1;400, c) Ubi2A #020698;1:400) showing UBB ϩ1 immunoreactive inclusions in the pyramidal cells of the CA1 area. Note their colocalization in various cells (OE). * ϭ capillary. d) In an adjacent section the same cell group was stained with UBB ϩ1 antiserum Ubi3 #050897 (1:400) whereas e) the absorption control of #020698 (1:400) was shown. Amino acid sequences against which the antibodies to UBB ϩ1 were raised are shown below panels a-e. Magnification bar ϭ 25 m. In FTD (#99005, d-f ) within the granular layer of the gd of the hippocampus, tangle-like (globoid) inclusions can be seen with MC1, UBB ϩ1 protein and ubiquitin. The same goes for the pyramidal cells of CA1 of the hippocampus. In PSP in the gray matter of the preforontal cortex both MC1 (g), UBB
ϩ1 protein (h), and ubiquitin (k) immunoreactive tangles can be seen. UBB ϩ1 protein (i) and ubiquitin (k) immunoreactive cytoplasmic inclusions can be seen in the glial cells of the white matter. In argyrophilic grain disease (l-n), abundant MC1, UBB ϩ1 , and ubiquitin-positive grains can be seen in the amygdala. Magnification bars in all panels ϭ 25 m; b) insert ϭ 15 m. dependent on the proteasome and requires ubiquitination of the lysine residues at positions 29 and 48 of UBB ϩ1 (11) . We wanted to test whether UBB ϩ1 expression is monitored by the proteasome in vivo in the hippocampus, an area affected in a number of neurodegenerative diseases. Lentiviral vectors (19, 20) were generated for UBB ϩ1 and a stable mutant of UBB ϩ1 that lacks the lysine residues at positions 29 and 48. We first tested the activity of the lentiviral vectors on SH-SY5Y neuroblastoma cells. UBB ϩ1 protein was expressed at low levels, whereas the K29,48R mutant is expressed at high levels (Fig. 6A) . The low expression of UBB ϩ1 is due to degradation by the proteasome, as addition of the proteasome inhibitor epoxomicin to the culture medium boosts the expression levels. The K29,48R mutant is not degraded by the proteasome and, as expected, expression is not stimulated by epoxomicin (which is slightly cytotoxic at these concentrations). Note the presence of ubiquitinated UBB ϩ1 protein, which is not present in the K29,48R mutant.
Subsequently, lentiviral vectors were spiked with a lentiviral GFP vector as a positive control and injected stereotactically in the adult rat hippocampus. The animals were perfused after 7 days and stained for UBB ϩ1 and GFP protein expression (Fig. 6B) . Clearly, very few cells are positive for UBB ϩ1 protein whereas the K29,48R mutant of UBB ϩ1 is abundantly present in the dentate gyrus of the hippocampus. The GFP vector gives similar expression in all animals, indicating that UBB ϩ1 protein in the neurologically intact brain is efficiently degraded by the ubiquitin-proteasome system. 
DISCUSSION
Previously we reported that we did not detect UBB ϩ1 protein in young controls as long as they were devoid of neuropathology, whereas in an elderly control (with some neuropathology) ⌬GU deleted transcripts and UBB ϩ1 protein were found (7) . The present study shows that UBB ϩ1 transcripts are generated in the human brain, irrespective of neuropathology, and can even be detected in nondemented controls. The process of molecular misreading (i.e., the generation of transcripts with a dinucleotide deletion) is apparently widespread in tissues, and neuropathological differences arise at the UBB ϩ1 protein level. The possibility that the accumulation of UBB ϩ1 protein is a secondary response to general neuronal dysfunctioning is unlikely, as indicated by the absence of staining in multiple sclerosis and in epilepsy. Moreover, molecular misreading was first described in apparently normally functioning vasopressin neurons (30) and also occurs in non-neuronal cells such as hepatocytes (31) . The data presented in this paper show that UBB ϩ1 accumulates in those neuropathological aggregates that also contain ubiquitin or ubiquitinated proteins. We have shown that UBB ϩ1 is a ubiquitin fusion degradation substrate that is ubiquitinated (11) . If UBB ϩ1 is expressed at low levels in cell lines, it can be degraded by the proteasome (Fig. 6A) (11) . However, at higher levels UBB ϩ1 can also inhibit the proteasome in vitro and in cell lines (10, 11) and subsequently induce cell death (12) . The expression of UBB ϩ1 protein could thus, after it has crossed a threshold, induce further accumulation of UBB ϩ1 . In the rat hippocampus transduced with lentiviral vectors, UBB ϩ1 protein is degraded efficiently by the proteasome whereas (K29,48R) mutant UBB ϩ1 protein, which is neither tagged by ubiquitin nor degraded by the proteasome, accumulates to high levels. Consequently, we suggest that accumulation of UBB ϩ1 protein is a marker for proteasomal dysfunction in the human brain.
The remarkable differential neuropathological accumulation of UBB ϩ1 protein (tauopathies vs. synucleinopathies) and the presence of UBB ϩ1 transcripts in both diseases could be caused by differences in protein degradation via the ubiquitin-proteasome system (32). As we cannot detect UBB ϩ1 protein in synucleinopathies, whereas tauopathies show high levels of UBB ϩ1 protein, we propose that specifically in tauopathies the proteasome is inhibited. Recently it has been shown biochemically that the proteasome is (partially) inhibited in Alzheimer disease (41, 47) . In vitro, tau paired helical filaments can inhibit the proteasome (47), which is further evidence for our proposal that UBB ϩ1 accumulates in tauopathies due to proteasome inhibition. An impairment of the ubiquitin-proteasome system resulting in the aggregation of aberrant proteins has been suggested in a number of neurological disorders (33) . Ubiquitinated dot-like structures and accumulation of ␤APP were observed in the nervous system of mice suffering from axonal gracile dystrophy due to an intragenic deletion of the UCH-L1 gene (43) . Furthermore, mutation of the E6-AP ubiquitin ligase gene can modify the number of nuclear inclusions in a mouse model for spinocerebellar ataxia-1 (SCA-1) (44) .
For Parkinson disease it has been suggested that ␣-synuclein, present in Lewy bodies, is mono-and di-ubiquitinated (34, 45) . It was shown that Parkin, which is mutated in autosomal recessive Parkinson disease, acts as an E3 ubiquitin ligase for ␣-synuclein (34) . Very recently a mutation in the DJ-1 gene was reported with autosomal recessive early-onset Parkinsonism (35) . Database comparison suggests the involvement of DJ-1 protein in the oxidative stress response. It is of great interest that ubiquitin-conjugation is not required for the degradation of oxidized proteins by the proteasome (36) . Indeed, it was reported that ␣-synuclein metabolism and aggregation are linked to ubiquitin-independent degradation by the proteasome (37) . The fact that in LBD as well as in MSA, ␣-synuclein is more prominent in cells than ubiquitin (Fig. 4) , also points to a less important role for general proteasome dysfunction in synucleinopathies (ref 38; R. A. I. de Vos, unpublished data). Nevertheless, it was also shown that a loss of ␣ subunits of the proteasome occurs in the substantia nigra in Parkinson's disease (39) . However, it has been suggested that a systemic, global disturbance in the catalytic activity and degradation ability of the proteasome itself is probably not causal for Parkinson disease (40, 42, 46) .
In conclusion, the presence of UBB ϩ1 protein in neuronal and glial inclusions acts as a reporter for an impaired activity of the proteasome in these cells. We believe that UBB ϩ1 levels can be used as a general measure for proteasome inhibition in a variety of human tissues (e.g., the liver; ref 31). The accumulation of ubiquitinated UBB ϩ1 could inhibit the proteasome even further (10 -12) , an aspect that is under further study. Apparently, proteasomal activity in tauopathies is more severely impaired compared with synucleinopathies.
